AN2 Therapeutics, Inc. Common Stock

AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Related tickers: ANTX.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ: MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.com shares dipped 10.1% to close at $212.01 on Monday. See how other analysts view this stock. Needham cut G1 Therapeutics, Inc. (NASDAQ: GTHX) price target from $14 to $12. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 1.1% to close at $4.48 on Monday. See how other analysts view this stock. Needham boosted the price target for Cadence Design Systems, Inc. (NASDAQ: CDNS) from $315 to $320. Needham analyst Charles Shi maintained a Buy rating. Cadence Design shares fell 1.7% to close at $306.58 on Monday. See how other analysts view this stock. B. Riley Securities cut The Children's Place, Inc. (NASDAQ:

Related tickers: CDNS, LSCC, PLCE, TRMB, ANTX, PYPL, ZI, GTHX, NAPA, MNDY.